Abstract: The invention relates to a novel tumor necrosis factor (TNF) homolog designated herein as TNF-related death ligand (TRDL). Isolated nucleic acid molecules are provided which encode TRDL. TRDL polypeptides are also provided, as are methods for identifying agonists and antagonists of TRDL activity.
Type:
Grant
Filed:
September 21, 1998
Date of Patent:
August 27, 2002
Assignee:
Pharmacia & Upjohn Company
Inventors:
Michael J. Bienkowski, Cynthia J. Mills, David A. Jones
Abstract: This patent application describes the treatment addictive disorders, psychoactive substance use disorders, intoxication disorders, inhalation disorders, alcohol addiction, tobacco addiction and or nicotine addiction comprising administering a therapeutically effective, nontoxic dose of pramipexole and derivatives and or pharmaceutically acceptable salts thereof to a patient.
Type:
Grant
Filed:
February 14, 2001
Date of Patent:
June 25, 2002
Assignee:
Pharmacia & Upjohn Company
Inventors:
Robert Clyde Marshall, Erik Ho Fong Wong, Philip F. Von Voigtlander
Abstract: A novel recombinant procaspase 8 protein lacking the death effector domains and a method for converting said novel procaspase protein to full active human caspase 8 by concentration of the procaspase 8 on a collection device.
Type:
Grant
Filed:
July 23, 1999
Date of Patent:
October 16, 2001
Assignee:
Pharmacia & Upjohn Company
Inventors:
Robert Leroy Heinrikson, Alfredo Giuseppe Tomasselli, Kenneth A. Koeplinger
Abstract: Antibiotic 10381a1, wherein R is hydrogen, is a cytosine-containing antibiotic producible by culturing the novel microorganism Streptomyces arginensis in an aqueous medium and isolation thereof. Derivatives wherein R is a C1 to C3 alkyl ester of antibiotic 10381a1, are also disclosed along with the pharmaceutically acceptable salts of both the native and esterified forms. Antibiotic 10381a1 inhibits the growth of selected species of yeast, fungi and bacteria. This invention also relates to a novel process for the preparation of the antibiotics 10381b and to a method of using antibiotics 10381b to promote growth in meat-producing animals. These antibiotics are also obtained by the fermentation of a nutrient medium with the novel microorganism Streptomyces arginensis and are active against selected species of bacteria.
Type:
Grant
Filed:
August 10, 1999
Date of Patent:
May 1, 2001
Assignee:
Pharmacia & Upjohn Company
Inventors:
Alexander D. Argoudelis, Franklin B. Shilliday, Alice L. Laborde, Scott E. Truesdell, Oldrich K. Sebek
Abstract: This invention comprises new formulations and methods of preparing a new formulations of prostaglandins and in particular dinoprost tromethamine, where the pH of the formulation is adjusted to between about 5.5-7.5 and where the the concentration of benzyl alcohol is between about 1.2 to 2.0 mg/ml.
Abstract: This invention provides a novel and useful purification step in the manufacture of a diamine pyrrolidine side chain intermediate for a quinolone antibiotic that allows production of the antibiotic in significantly greater yields and at lower costs than was previously possible. Salts, procedures and processes for preparing them, including the salt disclosed in Formula A-1, below, are also disclosed.
Abstract: This invention relates to intermediates and processes for the synthesis of camtothecin derivatives, such as irinotecan. Related procedures and compounds are disclosed, such as a method of making mappicine.
Abstract: The present invention relates to a method for the isolation and expression of a glycosyltransferase enzyme for use in the synthesis of oligosaccharide or polysaccharide structures on glycoproteins, glycolipids, or as free molecules. The gene coding for the enzyme N-acetylgalactosaminyltransferase and the polypeptide sequence of the acceptor peptide for the enzyme N-acetylgalactosaminyltransferase have been isolated and used for the control of glycosylation of a protein.
Abstract: This invention discloses novel forms of catalytic macro molecules that are related to cdc25B, a cell cycle specific phosphatase. These special domains of cdc25B, special fusions with GST, and unique peptides and proteins, their utility, and the method of making them are all described.
Type:
Grant
Filed:
May 1, 1997
Date of Patent:
June 13, 2000
Assignee:
Pharmacia & UpJohn Company
Inventors:
Martin R. Deibel, Jr., Anthony W. Yem, Cindy L. Wolfe
Abstract: This application discloses novel tetronic acids for the treatment of AIDS and other diseases caused by retroviruses.
Type:
Grant
Filed:
September 17, 1997
Date of Patent:
May 9, 2000
Assignee:
Pharmacia & Upjohn Company
Inventors:
Robert A. Chruscial, Linda L. Maggiora, Suvit Thaisrivongs, James M. Tustin, Clark W. Smith, Ruben A. Tommasi, Paul A. Aristoff, Harvey I. Skulnick, W. Jeffrey Howe
Abstract: This invention describes the full length sequence of human p56 protein (p56-1), a related homolog (p56-2) and the nucleic acids that code for these proteins. The sequences are provided in Charts 1, 2, 3, and 4 and the sequence listings of the application.
Abstract: Novel crystal forms of the fluoroquinolone, [S-(R*,S*)]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-[1-(methylam ino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid are disclosed. The forms are characterized by one methanol solvate form, and three anhydrous polymorphic forms, of which, Form III exhibits greatest stability and decreased hygroscopicity.
Type:
Grant
Filed:
May 1, 1996
Date of Patent:
November 16, 1999
Assignee:
Pharmacia & Upjohn Company
Inventors:
Xuanqiang Yu, William C. Schinzer, Michael J. Dunn, Robert Shih-Liang Chao, Dale S. Aldrich, Azhwarsamy Jeganathan, Michael S. Bergren
Abstract: Antibiotic 10381a.sub.1, wherein R is hydrogen, is a cytosine-containing antibiotic producible by culturing the novel microorganism Streptomyces arginensis in an aqueous medium and isolation thereof. Derivatives wherein R is a C.sub.1 to C.sub.3 alkyl ester of antibiotic 10381a.sub.1, are also disclosed along with the pharmaceutically acceptable salts of both the native and esterified forms. Antibiotic 10381a.sub.1 inhibits the growth of selected species of yeast, fungi and bacteria. This invention also relates to a novel process for the preparation of the antibiotics 10381b and to a method of using antibiotics 10381b to promote growth in meat-producing animals. These antibiotics are also obtained by the fermentation of a nutrient medium with the novel microorganism Streptomyces arginensis and are active against selected species of bacteria.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
November 16, 1999
Assignee:
Pharmacia & Upjohn Company
Inventors:
Alexander D. Argoudelis, deceased, Franklin B. Shilliday, Alice L. Laborde, Scott E. Truesdell, Oldrich K. Sebek
Abstract: Antibiotic 10381a.sub.1, wherein R is hydrogen, is a cytosine-containing antibiotic producible by culturing the novel microorganism Streptomyces arginensis in an aqueous medium and isolation thereof. Derivatives wherein R is a C.sub.1 to C.sub.3 alkyl ester of antibiotic 10381a.sub.1, are also disclosed along with the pharmaceutically acceptable salts of both the native and esterified forms. Antibiotic 10381a.sub.1 inhibits the growth of selected species of yeast, fungi and bacteria. This invention also relates to a novel process for the preparation of the antibiotics 10381b and to a method of using antibiotics 10381b to promote growth in meat-producing animals. These antibiotics are also obtained by the fermentation of a nutrient medium with the novel microorganism Streptomyces arginensis and are active against selected species of bacteria.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
November 9, 1999
Assignee:
Pharmacia & Upjohn Company
Inventors:
Alexander D. Argoudelis, deceased, Franklin B. Shilliday, Alice L. Laborde, Scott E. Truesdell, Oldrich K. Sebek
Abstract: This invention comprises novel substituted tetronic acid type compounds, 2, 4(3H, 5H)-furandiones, that are useful for the inhibition of the HIV protease enzyme. The compounds may be useful for the treatment of a person with AIDS or AIDS related diseases. The compounds may be used in the attempt to retard the further replication of any retrovirus containing the aspartyl protease enzyme. Compounds are represented by the formula below.
Type:
Grant
Filed:
July 28, 1997
Date of Patent:
November 2, 1999
Inventors:
Robert A. Chrusciel, Linda L. Maggiora, Suvit Thaisrivongs, James M. Tustin, Clark W. Smith, Ruben A. Tommasi, Paul A. Aristoff, Harvey I. Skulnick, W. Jeffrey Howe, Gordon L. Bundy
Abstract: This invention describes how to make and use several effective high volume screens for the discovery of inhibitors of specific protein:protein interactions, using aspects of the yeast two-hybrid system.